Rapamycin has long been studied as a potential longevity drug. But in 2025, the spotlight is shifting toward new and unexpected research directions—far beyond its classic role in slowing aging. Here are some of the most intriguing and lesser-known findings emerging this year: Rapamycin and Alzheimer’s: The First Human DataA recent phase I clinical trial…

Rapamycin has gone from being a life-saving drug for transplant patients to one of the most intriguing candidates for slowing aging. But beyond the headlines, new research is uncovering surprising benefits that could change how we think about health and longevity.Rapamycin is more than just a transplant drug. From boosting muscle mass to delaying menopause,…

Slowing aging is no longer just science fiction. A newly published scientific study shows that a combination of two FDA-approved drugs—rapamycin and trametinib—can significantly slow down aging and extend lifespan in mice. But here’s the most exciting part: it’s not just about living longer, it’s about living healthier. Two Different Pathways, One Shared Goal: A…

For generations, menopause has been a biological inevitability—a point of no return in a woman’s life that signals not only the end of fertility but also the start of increased health risks, from heart disease to osteoporosis. But what if menopause could be delayed? Not indefinitely, but just long enough to preserve health, well-being, and…

"How eating less (caloric restriction) and using Rapamycin might be related""How both affect the same core biological pathway: the mTOR pathway"Both caloric restriction (CR) and rapamycin influence the mTOR pathway, a central regulator of growth, metabolism, and aging.mTOR stands for "mechanistic Target of Rapamycin" — the very molecule that rapamycin targets, and the one whose…

Breakthrough Drug Duo Prolongs Mouse Lifespan by 30%A pioneering study from Germany's Max Planck Institute for Biology of Aging has unveiled that a combination of two existing cancer medications—rapamycin and trametinib—can extend the lifespan of mice by approximately 30%. This discovery offers promising insights into potential anti-aging therapies for humans.The Study's FindingsIn the research, mice…

A potential breakthrough in feline medicine is offering new hope to cat owners and veterinarians battling hypertrophic cardiomyopathy (HCM)—a leading cause of sudden death in cats. The drug rapamycin, long studied for its anti-aging properties, is now showing strong potential to prevent or even reverse the progression of HCM in cats.A Historic Milestone: FDA Approval…

The Dog Aging Project has reached an exciting milestone in its landmark study on healthy aging in dogs. The project recently announced that the first participants—Zoe and Jack—have completed their full three-year involvement in the Test of Rapamycin in Aging Dogs (TRIAD), a groundbreaking clinical trial exploring whether the drug rapamycin can slow or mitigate…

Early results from a phase 1 clinical trial suggest that weekly administration of rapamycin may significantly improve patient-reported outcome measures (PROMs) in individuals living with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The findings were presented by Stephanie L. Grach, MD, MS, assistant professor of medicine at Mayo Clinic, during the 2025 American College of Physicians (ACP)…

A medication once reserved for preventing organ rejection, rapamycin is now gaining momentum in the field of anti-aging science. Initially created as an immunosuppressive drug, rapamycin is now being studied for its potential to slow aging and prolong human life. With growing scientific support pointing to its possible benefits in fighting age-related illnesses, researchers are…